Effects of betaxolol on cardiohemodynamics and coronary circulation in anesthetized dogs: Comparison with atenolol and propranolol.

スポンサーリンク

概要

• 論文の詳細を見る

• Effects of betaxolol, a cardioselective β-adrenoceptor antagonist, on cardiohemodynamics and coronary circulation were investigated in two kinds of anesthetized open-chest dog preparations in comparison with those of atenolol and propranolol. When administered intravenously, betaxolol, atenolol and propranolol produced dose-dependent decreases in the heart rate (HR), maximum left ventricular dP/dt ((+)dP/dt), cardiac output (CO) and mean arterial pressure (MAP). Although all three drugs were almost equipotent in decreasing HR, betaxolol was much less potent than atenolol and propranolol in decreasing (+)dP/ dt. Betaxolol decreased the total peripheral resistance (TPR), whereas atenolol and propranolol increased it. In another series of experiments, when administered intravenously, betaxolol, atenolol and propranolol all produced a decrease in the myocardial oxygen consumption (MVO<SUB>2</SUB>) and an increase in the atrioventricular conduction time (AVCT). All three drugs were nearly equipotent in decreasing MVO<SUB>2</SUB>, although betaxolol was less potent than the other two drugs at higher doses (>300 μg/kg). Prolongation of AVCT with propranolol was stronger than those with betaxolol and atenolol. These results suggest that, unlike atenolol and propranolol, the decrease in TPR as well as β<SUB>1</SUB>-adrenoceptor blockade may be responsible for both the hypotensive effect of betaxolol and the decrease in MVO<SUB>2</SUB> with betaxolol. The result that the cardiodepressant effect of betaxolol was much less potent than those of atenolol and propranolol suggests that betaxolol would be more beneficial than the others in the treatment of ischemic heart desease.

• 公益社団法人 日本薬理学会の論文

著者

• Kitada Yoshimi

  Pharmaceutical Laboratory I Yokohama Research Center Mitsubishi Chemical Corporation

• BESSHO Hideki

  Pharmaceuticals Laboratory, Research Center, Mitsubishi Kasei Corporation

• Bessho Hideki

  Pharmaceuticals Laboratory, Life Science Research Sector, Research Center, Mitsubishi Kasei Corporation

• NARIMATSU Akihiro

  Pharmaceuticals Laboratory, Research Center, Mitsubishi Kasei Corporation

• SATOH Naoya

  Pharmaceuticals Laboratory, Research Center, Mitsubishi Kasei Corporation

• Tobe Akihiro

  Pharmaceuticals Laboratory, Life Science Research Sector, Research Center, Mitsubishi Kasei Corporation

• TOBE Akihiro

  Pharmaceuticals Laboratory, Research Center, Mitsubishi Kasei Corporation

• SUZUKI Jyunko

  Pharmaceuticals Laboratory, Research Center, Mitsubishi Kasei Corporation

• NARIMATSU Akihiro

  Pharmaceuticals Laboratory, Life Science Research Sector, Research Center, Mitsubishi Kasei Corporation

関連論文

• AGONIST ACTIVITY OF A NOVEL COMPOUND, BP-554,AT CENTRAL SEROTONIN-1A RECEPTORS
• Betaxolol, a β_1 -Adrenoceptor Antagonist, Inhibits Ca^-Induced Contraction in Skinned Renal Artery of the Dog
• Comparison of the Effects of MCI-154, a New Cardiotonic Agent, and Some Ca2+-Sensitizing Agents on the Response of the Contractile System to Ca2+ in Skinned Cardiac Muscle
• Effects of MCI-727, a New Anti-Ulcer Agent, on Plasma Secretin Concentration in Rats and Dogs and Pancreatic Exocrine Secretion in Rats.
• Vascular effects of betaxolol, a cardioselective .BETA.-adrenoceptor antagonist, in isolated rat arteries.
• In vitro characterization of the effects of MCI-154, anovel cardiotonic agent, on cardiac tissues.
• Effects of betaxolol on cardiohemodynamics and coronary circulation in anesthetized dogs: Comparison with atenolol and propranolol.
• Effects of MCI-727, a New Antiulcer Agent, on Various Gastric and Duodenal Lesions in Experimental Animals.
• Betaxolol, a cardioselective beta-adrenoceptor antagonist, attenuates ischemic myocardial acidosis in dogs.

スポンサーリンク